Latest Breaking News On - வினையூக்கி மருந்துகள் இன்க் - Page 2 : comparemela.com

Catalyst Pharmaceuticals, Inc.’s and KYE Pharmaceuticals’ Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi® June 03, 2021 13:20 ET | Source: Catalyst Pharmaceuticals, Inc. Catalyst Pharmaceuticals, Inc. - Without an NOC, Ruzurgi is without a Marketing Authorization in Canada - Matter Remanded Back to Health Canada to Provide a More Transparent Record of Its Decision in Light of Firdapse ® ’s Data Protection CORAL GABLES, Fla., June 03, 2021 (GLOBE NEWSWIRE) Catalyst Pharmaceuticals, Inc. ( Catalyst ) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing and commercializing novel high-quality medicines for patients living with rare diseases, and KYE Pharmaceuticals Inc. ( KYE ), a private company headquartered in Mississauga, Ontario and focused on bringing medicines that fulfill clinically significant unmet needs to the Canadian market, to

United statesDouglas reynoldsPatrickj mcenanyHealth canada onCatalyst pharmaceuticalsCanadian federal courtUs food drug administrationCatalyst pharmaceuticals incPharmaceuticals incHealth canadaMarketing authorizationRemanded backMore transparent recordIts decisionNew drug submissionJacobus pharmaceutical